Category Archives: Health

Latest From Health

Dr. Scott Gottlieb: A Clintonian Misdirection on Drug Prices

Hillary Clinton

Today’s Wall Street Journal contains an excellent op-ed by Dr. Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute. Dr. Gottlieb takes aim at the recent proposal offered by the campaign of Secretary Hillary Clinton to aggressively regulate the price of innovative prescription medicines. BIO shared many of those concerns in our statement and a related blog post. Dr. Gottlieb notes, “It’s important to distinguish between new medicines that are priced at Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Discover Trends and Investment Opportunities at the BIO Investor Forum

hyde pier

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event for private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences. The Forum will include candid fireside chats between biopharma CEOs, analysts, and other industry experts. Come hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2016. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Wall Street Journal: The Assault on Drug Innovation


Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Statement on Patient Access to Medicines

“As a general policy, BIO does not comment on matters related to individual company products or product pricing decisions, such as today’s news about Turing Pharmaceuticals. That said, the focus of the biotechnology industry is to develop innovative therapies and cures for patients. This means it is imperative not only that we develop these new medicines, but that all patients have access to them, as necessary to meet their healthcare needs. This principle should apply Read More >

Health  |  Leave a comment  |  Email This Post

Reality Check for AHIP: Competition Driving Down Costs for Hepatitis C Meds


Yesterday at a House Judiciary Committee hearing on competition in the healthcare marketplace, AHIP Executive Vice President Daniel Durham took the occasion to bemoan what he termed “monopoly pricing” in the pharmaceutical industry. He proceeded to cite the cost of two new specialty medicines for Hepatitis C, Gilead Sciences’ Sovaldi and Harvoni, as a “case study” of that problematic monopoly pricing. Durham’s analysis suffers from a particularly egregious flaw: Gilead and its products do not enjoy Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,